CSU Pipeline Update: Barzolvolimab Continues to Show Strong Efficacy
Barzolvolimab demonstrates rapid improvement in urticaria control with sustained efficacy in patients with chronic spontaneous urticaria (CSU) who are refractory to antihistamines, according to Phase 2 research presented at the American College of Allergy, Asthma & Immunology’s Annual Scientific Meeting (ACAAI) in Orlando, FL.